NLS Pharmaceutics Schedules Shareholder Meeting for Jan 7
Ticker: NCEL · Form: 6-K · Filed: Dec 17, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
NLS Pharmaceutics calling Jan 7 shareholder meeting - vote by Dec 16 record date.
AI Summary
NLS Pharmaceutics Ltd. announced an Extraordinary Shareholders' Meeting scheduled for January 7, 2025. Shareholders of record as of December 16, 2024, are eligible to vote on matters presented at the meeting. The filing includes the Notice of Meeting and Proxy Card.
Why It Matters
This meeting is crucial for shareholders to exercise their voting rights on important company matters, potentially influencing the future direction of NLS Pharmaceutics.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a shareholder meeting and does not contain significant financial or operational news that would immediately impact the company's risk profile.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- January 7, 2025 (date) — Extraordinary Shareholders' Meeting date
- December 16, 2024 (date) — Record date for shareholder eligibility
FAQ
What is the purpose of the Extraordinary Shareholders' Meeting?
The purpose is to allow shareholders to vote on matters presented at the meeting, as detailed in the Notice of Meeting and Proxy Card.
Who is eligible to vote at the meeting?
Shareholders of record who hold common and/or preferred shares of NLS Pharmaceutics Ltd. at the close of business on December 16, 2024 (11:59 pm CET) are entitled to vote.
When is the Extraordinary Shareholders' Meeting scheduled to take place?
The meeting is scheduled to be held on January 7, 2025.
What documents are attached to this 6-K filing?
The filing includes the Notice of Meeting and Proxy Card for the Extraordinary Shareholders' Meeting.
What is the company's principal executive office address?
The company's principal executive office is located at The Circle 6, 8058 Zurich, Switzerland.
Filing Stats: 310 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-12-17 16:30:02
Filing Documents
- ea0224882-6k_nlspharm.htm (6-K) — 12KB
- ea022488201ex99-1_nlspharma.htm (EX-99.1) — 86KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- 0001213900-24-109788.txt ( ) — 101KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: December 17, 2024 By: /s/ Alexander C. Zwyer Name: Alexander C. Zwyer Title: Chief Executive Officer 3